



PRESS RELEASE

First Trading Day of Crucell Shares on SWX Swiss Exchange

Leiden, The Netherlands, February 22, 2006 – Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that under the Exchange Offer on Berna A.G. approximately 97.0% of all issued Berna shares have definitely been tendered, and that the offer has now been settled.

In terms of the full settlement of the offer, 16,691,492 ordinary shares in Crucell have been issued and listed today on Euronext Amsterdam. As a result there are now 58,112,105 shares outstanding.

Today is also the first trading day of Crucell shares on the SWX Swiss Exchange (ticker symbol: SW CRX).

Crucell N.V. intends to pursue, following settlement, the squeeze-out of the remaining minority shareholdings and to delist Berna Biotech A.G. in connection therewith.

About Crucell

Crucell (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) is a biotechnology company focused on research, development, production and worldwide marketing of vaccines and antibodies that combat infectious diseases. The vaccines are sold in both private and public sectors. In Crucell's portfolio hepatitis B vaccines and a virosomal influenza vaccine play an important role. Travel vaccines are also marketed including the only available oral anti-typhoid vaccine. The Company's well-filled pipeline consists of early and late-stage products. Some of Crucell's products are based on its unique PER.C6[®] production technology. The Company also licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden, The Netherlands, has subsidiaries in Switzerland, elsewhere in Europe and Korea, and has approximately 1000 employees. For more information, please visit www.crucell.com.

Forward-looking statements

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on April 14, 2005, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.

Harry Suykerbuyk

Director Investor Relations and Corporate Communications

Tel. +31 (0)71 524 8718

h.suykerbuyk@crucell.com